HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $113.
August 01, 2024 | 10:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioNTech and maintained a price target of $113.
The reiteration of a Buy rating and maintenance of a $113 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100